title: A single-centre, before-after study of the short- and long-term efficacy of Narivent(®) in the treatment of nasal congestion.
abstract: OBJECTIVE
  Nasal congestion is a common symptom in allergic and nonallergic rhinitis, rhinosinusitis and nasal polyposis. The present study evaluated the clinical effectiveness of Narivent(®), an osmotically-acting medical device with anti oedematous and anti-inflammatory effects, in nasal congestion.
  
  
  METHODS
  A single-centre, prospective study with a pre- post design and consecutive patient enrolment was conducted in an Italian otolaryngology department. Patients with persistent nasal congestion were allocated to treatment groups as follows: group 1 (n = 36) treated for 7 days; group 2 (n = 56) treated for 30 days. In each group, patients received two puffs of Narivent(®) into each nostril twice daily. Symptom severity was assessed subjectively on a 0-10 visual analogue scale, and objectively by the presence/absence of signs and symptoms. Differences in subjective and objective severity measures before and after treatment were compared using Wilcoxon's signed rank test.
  
  
  RESULTS
  All symptoms and objective scores improved after treatment with Narivent(®) for 7 or 30 days and no adverse effects were reported by the patients in either group.
  
  
  CONCLUSIONS
  Narivent(®) appears to be efficacious in treating nasal congestion over a 7- or a 30-day period.
authors.affiliation: Ear, Nose and Throat Department, San Giovanni Addolorata Hospital, Rome, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Damiani
authors.forename: A
authors.initials: A
authors.lastname: Camaioni
authors.forename: C
authors.initials: C
authors.lastname: Viti
authors.forename: A S
authors.initials: AS
authors.lastname: Scirè
authors.forename: G
authors.initials: G
authors.lastname: Morpurgo
authors.forename: D
authors.initials: D
authors.lastname: Gregori
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003511:Cyclohexanols / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D019695:Glycyrrhizic Acid / Q000008:administration & dosage*; D006801:Humans; D006984:Hypertrophy / Q000188:drug therapy; D008297:Male; D008353:Mannitol / Q000008:administration & dosage*; D008875:Middle Aged; D039821:Monoterpenes / Q000008:administration & dosage*; D015508:Nasal Obstruction / Q000188:drug therapy*; D016896:Treatment Outcome; D014420:Turbinates / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D003511:Cyclohexanols; D004338:Drug Combinations; D039821:Monoterpenes; C582426:narivent; D008353:Mannitol; D019695:Glycyrrhizic Acid